GLP1R and type 2 diabetes mellitus: In August of 2025, Wang and colleagues published a systematic review and meta-analysis quantifying the effects of glucagon-like peptide-1 receptor agonist (GLP1RA) drugs on skeletal muscle mass in patients with type 2 diabetes mellitus.